ALS Association - Joint Call with MGH Neurological Clinical Research Institute for Phase II Clinical Trials ($ 800,000)
The ALS Association and the Massachusetts General Hospital Neurological Clinical Research Institute (NCRI) announce a call for Phase II clinical trial applications for novel, high potential treatments for ALS. Deadline for submitting letters of intent is May 20, 2013. The goal is to expedite the process of bringing new treatments forward for testing in people with ALS and to measure if that therapeutic agent is reaching its target. The call is intended for academic-industry partnerships, including pharmaceutical, biotherapeutic/biotechnology companies, academic members of the Northeast ALS Consortium (NEALS), and ALS scientists throughout the world. Clinical research support up to 800,000 is available.
The mission of the ALS Association (ALSA) is to find a cure for amyotrophic lateral sclerosis (often called Lou Gehrig's disease). ALSA welcomes applications for support of promising, quality, innovative research in the field of amyotrophic lateral sclerosis.